Mondragon Insurance Solutions Offers Clients The Best Insurance Solutions In The Highly Litigious California

Mondragon Insurance Solutions announces the availability of superior insurance policies for Californian law firms.

Mondragon Insurance Solutions is a highly reputable insurance brokerage with a record of helping attorney law firms get the best coverage to protect them against claims of malpractice.

California is a very litigious state, and lawyers and law firms need to have access to comprehensive insurance protection to ensure that they can operate as a well-run and healthy law firm that cares for its clients.

“California is in the middle of an insurance crisis as insurance rates have gone through the roof, and carriers are leaving California in droves,” says the spokesperson for Mondragon Insurance Solutions. “As professional insurance costs continue to rise, having a broker working as your advocate can save you hundreds, even thousands of dollars, all at no additional cost. Malpractice insurance is one of the bigger expenses a law firm incurs, so our expertise in the insurance arena ensures that our clients get the best coverage at the best premium rates available.”

Debra L. Mondragon, the founder of this established insurance agency, utilizes her experience to provide options from quality insurance carriers that protect law firms when a malpractice claim arises. Debra has expertise in law firm risk management. She utilizes her extensive experience and leverages the various carriers and policy differences to recommend the best insurance policy for the firm.

Mondragon Insurance Solutions also assists with General Liability (GL), Network Breach/Cyber liability insurance policies, Workers’ Compensation (WC), Employment Practice (ELI) policies as well as many other types of insurance.

Applicants can provide a short form worksheet to Mondragon Insurance Solutions to get several options. The brokers at Mondragon Insurance Solutions review the worksheet to ensure it is presented in the best possible light before submitting it to various insurance companies that offer solutions to protect against claims or potential malpractice claims.

Please visit our website or contact me for more information: https://mondragoninsurancesolutions.com/ 

Everyone is experiencing premium increases in insurance.  Some even face policy cancellations or restricted coverage and non-renewals. To run a lucrative law firm or business in California, it is increasingly important that companies have the proper coverage in place to avoid being wiped out.

Insurance companies are free to select the regions where they operate in California and nationwide. Many are facing enormous challenges due to frequent and severe adverse developments that can lead to loss of life and property which in turn affects all lines of insurance currently being offered in California.

It becomes imperative to use the services of an insurance specialist who advocates for the consumer. They can assist in obtaining the necessary insurance coverage to protect against such risks and maintain a sustainable business. Mondragon Insurance Solutions is well-equipped to assist in this regard.

The insurance industry in California faces a shortage of carriers willing to underwrite risks within the state. There is a concerning trend of insurance companies withdrawing entirely from California. Consequently, the premiums for all types of insurance have increased and are expected to continue rising until the overall stability of the insurance industry in California is achieved.

For more information, visit https://mondragoninsurancesolutions.com/ 

www.insurancejournal.com

About Mondragon Insurance Solutions:

Mondragon Insurance Solutions stands out by providing California Lawyers & Law firms with unique options for Professional Liability Insurance (E&O/Errors & Omissions) policies. The owner, Debra L. Mondragon, has specialized in this field since 1995 and acts as a broker. She is a trusted advocate for her clients. She works on behalf of her clients and not on behalf of any particular insurance carrier, ensuring that her client’s needs and interests are always the top priority.

Media Contact
Company Name: Mondragon Insurance Solutions
Contact Person: Debra L. Mondragon
Email: Send Email
Phone: 424-330-2011
City: Simi Valley
State: CA
Country: United States
Website: https://mondragoninsurancesolutions.com/

Angelman Syndrome Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Ovid Therapeutics, GeneTx Biotherapeutics

Angelman Syndrome pipeline constitutes 10+ key companies continuously working towards developing 10+ Angelman Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Angelman Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Angelman Syndrome Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Angelman Syndrome Market.

 

Some of the key takeaways from the Angelman Syndrome Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Angelman Syndrome treatment therapies with a considerable amount of success over the years. Angelman Syndrome Key players such as – Taysha Gene Therapies, PTC Therapeutics, GEXVal, Roche, Ionis Pharmaceuticals, Ultragenyx Pharmaceutical, Neuren Pharmaceuticals , and others, are developing therapies for the Angelman Syndrome treatment 
  • Angelman Syndrome Emerging therapies such as – AAV-mediated UBE3A Gene Replacement therapy, GT-AS, GXV 001, RG 6091, ION582, GTX-102, NNZ-2591, and others are expected to have a significant impact on the Angelman Syndrome market in the coming years. 
  • In November 2023, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has reported the successful completion of enrollment and positive initial results from Part 1 of the ongoing HALOS Phase 1/2a trial of ION582 (BIIB121) in Angelman syndrome. The study demonstrated that ION582 was generally well-tolerated, and it exhibited promising trends in electroencephalogram (EEG) activity and early indications of clinical improvement. However, these findings will require confirmation upon the analysis of the complete dataset expected by mid-2024. The results were presented at the FAST (Foundation for Angelman Syndrome Therapeutics) Summit, with the presentation available for reference. Part 1 of the HALOS trial consists of a three-month, open-label, multiple-ascending dose study, while Part 2 involves a long-term extension study evaluating ION582 for an additional 12 months.
  • In May 2023, Ultragenyx Pharmaceutical revealed that the US Food and Drug Administration (FDA) has reviewed and approved modifications to the protocol of its Phase I/II trial for GTX-102, aimed at treating children with Angelman syndrome.
  • In July 2022, Neuren Pharmaceuticals Limited initiated an open-label study of the safety, tolerability, and pharmacokinetics of oral NNZ-2591 in Angelman Syndrome. It is a study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome.

 

Angelman Syndrome Overview

Angelman syndrome is a rare genetic disorder that primarily affects the nervous system, causing developmental disabilities and neurological problems. It is typically characterized by severe intellectual disability, developmental delay, speech impairment, movement and balance issues, seizures, and a characteristic behavioral phenotype that includes frequent laughter and a happy demeanor.

 

Get a Free Sample PDF Report to know more about Angelman Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/angelman-syndrome-pipeline-insight

 

Angelman Syndrome Pipeline Therapeutics Assessment 

  • Angelman Syndrome Assessment by Product Type
  • Angelman Syndrome By Stage and Product Type
  • Angelman Syndrome Assessment by Route of Administration
  • Angelman Syndrome By Stage and Route of Administration
  • Angelman Syndrome Assessment by Molecule Type
  • Angelman Syndrome by Stage and Molecule Type

 

DelveInsight’s Angelman Syndrome Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Angelman Syndrome product details are provided in the report. Download the Angelman Syndrome pipeline report to learn more about the emerging Angelman Syndrome therapies 

 

Emerging Angelman Syndrome Drugs Under Different Phases of Clinical Development Include:

  • AAV-mediated UBE3A Gene Replacement therapy: Taysha Gene Therapies
  • GT-AS: PTC Therapeutics
  • GXV 001: GEXVal
  • RG 6091: Roche
  • ION582: Ionis Pharmaceuticals
  • GTX-102: Ultragenyx Pharmaceutical
  • NNZ-2591: Neuren Pharmaceuticals 

 

Angelman Syndrome Pipeline Analysis:

The Angelman Syndrome pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Angelman Syndrome treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Angelman Syndrome Treatment.
  • Angelman Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Angelman Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Angelman Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Get a Free Sample PDF Report to know more about Angelman Syndrome Pipeline Assessment

 

Angelman Syndrome Pipeline Market Drivers

  • Improving Healthcare Infrastructure
  • Rising investments aimed at research and development activities to extract enhanced and more effective solutions for the treatment of Angelman syndrome

 

Angelman Syndrome Pipeline Market Barriers

  • Lack of awareness regarding the Angelman Syndrome
  • Misdiagnosis of the angelman syndrome as cerebral palsy or autism

 

Scope of Angelman Syndrome Pipeline Drug Insight    

  • Coverage: Global
  • Key Angelman Syndrome Companies: Taysha Gene Therapies, PTC Therapeutics, GEXVal, Roche, Ionis Pharmaceuticals, Ultragenyx Pharmaceutical, Neuren Pharmaceuticals , and others
  • Key Angelman Syndrome Therapies: AAV-mediated UBE3A Gene Replacement therapy, GT-AS, GXV 001, RG 6091, ION582, GTX-102, NNZ-2591, and others
  • Angelman Syndrome Therapeutic Assessment: Angelman Syndrome current marketed and Angelman Syndrome emerging therapies
  • Angelman Syndrome Market Dynamics:  Angelman Syndrome market drivers and Angelman Syndrome market barriers 

 

Request for Sample PDF Report for Angelman Syndrome Pipeline Assessment and clinical trials

 

Table of Contents

1

Angelman Syndrome Report Introduction

2

Angelman Syndrome Executive Summary

3

Angelman Syndrome Overview

4

Angelman Syndrome- Analytical Perspective In-depth Commercial Assessment

5

Angelman Syndrome Pipeline Therapeutics

6

Angelman Syndrome Late Stage Products (Phase II/III)

7

Angelman Syndrome Mid Stage Products (Phase II)

8

Angelman Syndrome Early Stage Products (Phase I)

9

Angelman Syndrome Preclinical Stage Products

10

Angelman Syndrome Therapeutics Assessment

11

Angelman Syndrome Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Angelman Syndrome Key Companies

14

Angelman Syndrome Key Products

15

Angelman Syndrome Unmet Needs

16 

Angelman Syndrome Market Drivers and Barriers

17

Angelman Syndrome Future Perspectives and Conclusion

18

Angelman Syndrome Analyst Views

19

Appendix

20

About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Angelman Syndrome Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Ovid Therapeutics, GeneTx Biotherapeutics

Gastrointestinal Stromal Tumor Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | IDRx, Inc

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Gastrointestinal Stromal Tumor pipeline constitutes 25+ key companies continuously working towards developing 28+ Gastrointestinal Stromal Tumor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Gastrointestinal Stromal Tumor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Gastrointestinal Stromal Tumor Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastrointestinal Stromal Tumor Market.

 

Some of the key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Gastrointestinal Stromal Tumor treatment therapies with a considerable amount of success over the years. 
  • Gastrointestinal Stromal Tumor companies working in the treatment market are IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., Cogent Biosciences, Ascentage Pharma Group, Daiichi Sankyo Company, and others, are developing therapies for the Gastrointestinal Stromal Tumor treatment 
  • Emerging Gastrointestinal Stromal Tumor therapies in the different phases of clinical trials are- IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, PLX9486, Nilotinib, HQP1351, DS 6157, and others are expected to have a significant impact on the Gastrointestinal Stromal Tumor market in the coming years.   
  • In October 2023, Combining regorafenib with avelumab showed promising long-term advantages for certain individuals diagnosed with gastrointestinal stromal tumors (GIST).
  • In June 2022, The US Food and Drug Administration (FDA) gave Immunicum AB’s ilixadencel an Orphan Drug Designation (ODD) for the management of Gastrointestinal Stromal Tumours (GIST)
  • In January 2022, A Phase III open-label, multinational, multicenter research of CGT9486 in conjunction with sunitinib was started by Cogent Biosciences, Inc. There will be about 426 patients enrolled in this multi-part trial.
  • The selective tyrosine kinase inhibitor PLX9486 is intended to effectively inhibit D816V and other KIT exon 17 mutations. It is challenging to obtain wide therapeutic KIT inhibition since the majority of patients with imatinib-resistant GIST have both primary and secondary KIT mutations, frequently including secondary mutations on exon 17 and exon 13. In the first half of 2023, Cogent Biosciences, Inc. will present preliminary findings from PEAK, a registrational randomised, open-label, international Phase III clinical trial for patients with gastrointestinal stromal tumours (GIST)
  • In June 2022, The third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351) was studied in a Phase Ib/II research in patients with metastatic gastrointestinal stromal tumours (GIST) who had either failed or been resistant to earlier TKI treatment. The results were released by Ascentage Pharma. Olverembatinib (HQP1351), according to the manufacturer, showed encouraging anticancer efficacy in patients with gastrointestinal stromal tumours (GIST) that were resistant to tyrosine kinase inhibitors (TKIs) but low in succinate dehydrogenase (SDH). Olverembatinib will be jointly developed and commercialised in the Chinese cancer market by Ascentage Pharma and Innovent Biologics (1801.HK) beginning in July 2021
  • In January 2022, The lead candidate, THE-630, is being evaluated in patients with advanced gastrointestinal stromal tumours (GIST) in Theseus’ current Phase I/II research, according to a statement from the company. The first data set is anticipated in 1H 2023. The company’s flagship candidate THE-630 was given orphan drug designation (ODD) by the US Food and Drug Administration in February 2022 for the treatment of patients with advanced gastrointestinal stromal tumours (GIST)

 

Gastrointestinal Stromal Tumor Overview

A gastrointestinal stromal tumor (GIST) is a type of soft tissue sarcoma that develops in the gastrointestinal (GI) tract, which includes the stomach, small intestine, large intestine, rectum, and esophagus. GISTs typically originate from specialized cells in the wall of the GI tract called interstitial cells of Cajal (ICCs), which regulate the movement of food and fluids through the digestive system.

 

Get a Free Sample PDF Report to know more about Gastrointestinal Stromal Tumor Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight

 

Emerging Gastrointestinal Stromal Tumor Drugs Under Different Phases of Clinical Development Include:

  • IDRX-42: IDRx, Inc
  • THE-630: Theseus Pharmaceuticals
  • PDR001: Novartis
  • Crenolanib: Arog Pharmaceuticals, Inc.
  • Famitinib: Jiangsu HengRui Medicine Co., Ltd.
  • CGT9486: Cogent Biosciences, Inc.
  • PLX9486: Cogent Biosciences
  • Nilotinib: Novartis
  • HQP1351: Ascentage Pharma Group
  • DS 6157: Daiichi Sankyo Company

 

Gastrointestinal Stromal Tumor Route of Administration

Gastrointestinal Stromal Tumor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

 

Gastrointestinal Stromal Tumor Molecule Type

Gastrointestinal Stromal Tumor Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment

  • Gastrointestinal Stromal Tumor Assessment by Product Type
  • Gastrointestinal Stromal Tumor By Stage and Product Type
  • Gastrointestinal Stromal Tumor Assessment by Route of Administration
  • Gastrointestinal Stromal Tumor By Stage and Route of Administration
  • Gastrointestinal Stromal Tumor Assessment by Molecule Type
  • Gastrointestinal Stromal Tumor by Stage and Molecule Type

 

DelveInsight’s Gastrointestinal Stromal Tumor Report covers around 28+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Gastrointestinal Stromal Tumor product details are provided in the report. Download the Gastrointestinal Stromal Tumor pipeline report to learn more about the emerging Gastrointestinal Stromal Tumor therapies

 

Some of the key companies in the Gastrointestinal Stromal Tumor Therapeutics Market include:

Key companies developing therapies for Gastrointestinal Stromal Tumor are –  Novartis, Bayer, Pfizer, Deciphera Pharmaceuticals, Blueprint Medicines Corporation, Loxo Oncology, Roche, Arog Pharmaceuticals, Taiho Pharmaceutical, Turning Point Therapeutics, Inc., Cogent Biosciences, Inc., Plexxikon Inc., Theseus Pharmaceuticals, Exelixis, Inc., Ipsen, Bristol-Myers Squibb, Takeda, and others.

 

Gastrointestinal Stromal Tumor Pipeline Analysis:

The Gastrointestinal Stromal Tumor pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Gastrointestinal Stromal Tumor with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor Treatment.
  • Gastrointestinal Stromal Tumor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Gastrointestinal Stromal Tumor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gastrointestinal Stromal Tumor market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Gastrointestinal Stromal Tumor drugs and therapies

 

Gastrointestinal Stromal Tumor Pipeline Market Drivers

  • Increasing prevalence of digestive disorders, increasing investment of biotechnology and pharmaceutical industries in research and development, availability of funds is likely to drive the growth of the Gastrointestinal Stromal Tumor are some of the important factors that are fueling the Gastrointestinal Stromal Tumor Market.

 

Gastrointestinal Stromal Tumor Pipeline Market Barriers

  • However, higher cost associated with the treatment procedure and hence, this is a major fact that might be responsible for slowing the market growth, reimbursement Policies and other factors are creating obstacles in the Gastrointestinal Stromal Tumor Market growth.

 

Scope of Gastrointestinal Stromal Tumor Pipeline Drug Insight    

  • Coverage: Global
  • Key Gastrointestinal Stromal Tumor Companies: IDRx, Inc, Theseus Pharmaceuticals, Novartis, Arog Pharmaceuticals, Inc., Jiangsu HengRui Medicine Co., Ltd., Cogent Biosciences, Inc., Cogent Biosciences, Ascentage Pharma Group, Daiichi Sankyo Company, and others
  • Key Gastrointestinal Stromal Tumor Therapies: IDRX-42, THE-630, PDR001, Crenolanib, Famitinib, CGT9486, PLX9486, Nilotinib, HQP1351, DS 6157, and others
  • Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
  • Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers 

 

Request for Sample PDF Report for Gastrointestinal Stromal Tumor Pipeline Assessment and clinical trials

 

Table of Contents 

1. Gastrointestinal Stromal Tumor Report Introduction

2. Gastrointestinal Stromal Tumor Executive Summary

3. Gastrointestinal Stromal Tumor Overview

4. Gastrointestinal Stromal Tumor- Analytical Perspective In-depth Commercial Assessment

5. Gastrointestinal Stromal Tumor Pipeline Therapeutics

6. Gastrointestinal Stromal Tumor Late Stage Products (Phase II/III)

7. Gastrointestinal Stromal Tumor Mid Stage Products (Phase II)

8. Gastrointestinal Stromal Tumor Early Stage Products (Phase I)

9. Gastrointestinal Stromal Tumor Preclinical Stage Products

10. Gastrointestinal Stromal Tumor Therapeutics Assessment

11. Gastrointestinal Stromal Tumor Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Gastrointestinal Stromal Tumor Key Companies

14. Gastrointestinal Stromal Tumor Key Products

15. Gastrointestinal Stromal Tumor Unmet Needs

16 . Gastrointestinal Stromal Tumor Market Drivers and Barriers

17. Gastrointestinal Stromal Tumor Future Perspectives and Conclusion

18. Gastrointestinal Stromal Tumor Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastrointestinal Stromal Tumor Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | IDRx, Inc

Dengue Fever Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Kino Pharma, Abivax, Plex Pharma, Codagenix, Atea Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dengue Fever pipeline constitutes 10+ key companies continuously working towards developing 10+ Dengue Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Dengue Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Dengue Fever Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dengue Fever Market.

 

Some of the key takeaways from the Dengue Fever Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Dengue Fever treatment therapies with a considerable amount of success over the years. 
  • Dengue Fever companies working in the treatment market are  Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others, are developing therapies for the Dengue Fever treatment 
  • Emerging Dengue Fever therapies such as – anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others are expected to have a significant impact on the Dengue Fever market in the coming years.
  • In Febuary 2024, The TAK-003 vaccine represents a novel approach to combatting dengue fever in regions heavily impacted by the disease.

 

Dengue Fever Overview

Dengue fever is a viral infection transmitted primarily by the Aedes mosquito, particularly Aedes aegypti. It is caused by the dengue virus, which belongs to the Flaviviridae family. Dengue fever is prevalent in tropical and subtropical regions, including Southeast Asia, the Pacific Islands, the Caribbean, and parts of Central and South America.

 

Get a Free Sample PDF Report to know more about Dengue Fever Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dengue-fever-pipeline-insight

 

Emerging Dengue Fever Drugs Under Different Phases of Clinical Development Include:

  • Research programme: anti-RNA virus therapeutics – Kino Pharma
  • ABX220: Abivax
  • Infectious diseases therapeutics Programme: Plex Pharmaceuticals
  • CDX DENV: Codagenix
  • AT-752: Atea Pharmaceuticals
  • LD vehicle-GNP: Emergex Vaccines
  • VIS513: Visterra
  • JNJ-64281802: Janssen Research & Development
  • TV003: Merck & Co.
  • V 503: Takeda

 

Route of Administration

Dengue Fever pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Small molecules
  • Proteins
  • Monoclonal antibodies
  • Product Type

 

Dengue Fever Pipeline Therapeutics Assessment

  • Dengue Fever Assessment by Product Type
  • Dengue Fever By Stage and Product Type
  • Dengue Fever Assessment by Route of Administration
  • Dengue Fever By Stage and Route of Administration
  • Dengue Fever Assessment by Molecule Type
  • Dengue Fever by Stage and Molecule Type

 

DelveInsight’s Dengue Fever Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Dengue Fever product details are provided in the report. Download the Dengue Fever pipeline report to learn more about the emerging Dengue Fever therapies

 

Some of the key companies in the Dengue Fever Therapeutics Market include:

Key companies developing therapies for Dengue Fever are – Takeda Pharmaceutical Co Ltd, BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, 60 Degrees Pharmaceuticals LLC, and Abivax SA among others.

 

Dengue Fever Pipeline Analysis:

The Dengue Fever pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dengue Fever with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Fever Treatment.
  • Dengue Fever key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dengue Fever Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue Fever market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Dengue Fever drugs and therapies

 

Dengue Fever Pipeline Market Drivers

  • Fastest spreading mosquito-borne viral disease, search of novel tools and innovative strategies to interrupt transmission of dengue, integration of vector management approaches is encouraged are some of the important factors that are fueling the Dengue Fever Market.

 

Dengue Fever Pipeline Market Barriers

  • However, challenging research due to multiple stereotypes, disease risks may change and shift with climate change in tropical and subtropical areas and other factors are creating obstacles in the Dengue Fever Market growth.

 

Scope of Dengue Fever Pipeline Drug Insight    

  • Coverage: Global
  • Key Dengue Fever Companies: Kino Pharma, Abivax, Plex Pharmaceuticals, Codagenix, Atea Pharmaceuticals, Emergex Vaccines, Visterra, Janssen Research & Development, Merck & Co., Takeda, and others
  • Key Dengue Fever Therapies: anti-RNA virus therapeutics, ABX220, Infectious diseases therapeutics Programme, CDX DENV, AT-752, LD vehicle-GNP, VIS513, JNJ-64281802, TV003, V 503, and others
  • Dengue Fever Therapeutic Assessment: Dengue Fever current marketed and Dengue Fever emerging therapies
  • Dengue Fever Market Dynamics: Dengue Fever market drivers and Dengue Fever market barriers 

 

Request for Sample PDF Report for Dengue Fever Pipeline Assessment and clinical trials

 

Table of Contents

1

Dengue Fever Report Introduction

2

Dengue Fever Executive Summary

3

Dengue Fever Overview

4

Dengue Fever- Analytical Perspective In-depth Commercial Assessment

5

Dengue Fever Pipeline Therapeutics

6

Dengue Fever Late Stage Products (Phase II/III)

7

Dengue Fever Mid Stage Products (Phase II)

8

Dengue Fever Early Stage Products (Phase I)

9

Dengue Fever Preclinical Stage Products

10

Dengue Fever Therapeutics Assessment

11

Dengue Fever Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Dengue Fever Key Companies

14

Dengue Fever Key Products

15

Dengue Fever Unmet Needs

16 

Dengue Fever Market Drivers and Barriers

17

Dengue Fever Future Perspectives and Conclusion

18

Dengue Fever Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dengue Fever Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Kino Pharma, Abivax, Plex Pharma, Codagenix, Atea Pharma

Randall Flores, Author of How I Lost My Kidneys In China – A Twenty-Five-Year Overindulgent Odyssey, Recognized as a Finalist in International Book Contest

From student to adventurer to terrifying health crisis, author Randall Flores shares his twenty-five-year overindulgent odyssey through China’s modernization period in his debut memoir, How I Lost My Kidneys In China. The book has been recognized for its outstanding writing, design and overall market appeal out of thousands of books submitted into the Book Excellence Awards.

Randall Flores is the multiple award-winning author of How I Lost My Kidneys In China, a revelatory memoir that chronicles his twenty-five-year adventure through Asia. A masterful literary debut, the book has been met with widespread acclaim and caught the attention of movie studios.

Originally from Chicago, Randall learned Mandarin at Phillips Academy in Andover and furthered his education by attending the University of Rochester and Peking University, obtaining degrees in Chinese and economics.

He now resides in California with his wife and kids. Randall spends his time staying informed on global affairs and writing a second memoir about a trip to Pamplona for the running of the bulls.

This one-on-one interview shares Randall Flores’s background and experience in writing How I Lost My Kidneys In China – A Twenty-Five-Year Overindulgent Odyssey.

Tell us about How I Lost My Kidneys In China.

My memoir takes the reader through the transformative changes in the Greater China Region over twenty-five years. It gives readers a front-row seat to the fast-paced rise of a global superpower while detailing my journey, navigating my way to the top before succumbing to health issues. It also depicts the expat experience and the risks of working in the supply chain.

It was a life like no other.

What inspired you to write How I Lost My Kidneys In China – A Twenty-Five-Year Overindulgent Odyssey?

My introduction to Chinese took place at Andover Academy during the summer of 1987. Upon my return to Chicago, people became interested when I mentioned I had studied Mandarin. At the time, China was like a sleeping giant, and the primary worry was Japan’s potential world domination. I predicted that the Dragon of the East would awaken, causing a surge in the need for individuals proficient in Chinese.

With gradual improvement, I reached the prestigious halls of Peking University, the second-best college in China (ranked 17th worldwide). Back in 1990, the number of international students was around a hundred. Now, the number has increased to several thousand. Luckily, I got there before the stampede.

After moving to Hong Kong in 1994, I started working for an importer of footwear and spent the next two decades touring over five hundred factories across fifteen provinces. My exciting escapade took a sudden twist when excessive alcohol consumption resulted in kidney failure.

Over the course of my journey, I played multiple roles, such as a high-flying executive, a nuts-and-bolts factory guy, a road warrior, a family man, a boss, an adventurer, a connoisseur of food and drink, a teacher, a human resources manager, a fixer, an accountant, a runner, a tour guide, and an ill person.

My unique experiences left people informed, shocked, and entertained. The response was always, “You should write these down.” So I did. I also desired to record the development speed of everything around me and the significant transformations I observed. Finally, I aimed to detail the pain and hardship that an end-stage renal failure patient goes through. I don’t recommend it.

How did you feel when you found out you received a Book Excellence Award?

In today’s media landscape, books struggle to capture people’s attention. The Book Excellence Awards not only recognizes quality work, but also helps authors broaden their audience. It is an accolade that would please any author.

How did your background and experience influence your writing?

Since this is a true story, everything from my history was helpful. My passports, pictures, videos, and weekly expense reports were indispensable.

Accuracy should be the focus of any memoir, and my preparation ensured I achieved that.

What is one message you would like readers to remember?

Opt for the unconventional path and embrace adventure. While there may be hurdles, the journey will be fulfilling.

Purchasing the Book

How I Lost My Kidneys In China – A Twenty-Five-Year Overindulgent Odyssey has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Reviewer Kevin Daly writes, “A quick and easy read, detailing the life of an expat, who braves the Far East as a young man and succeeds, but at a cost. A true cautionary tale, we follow Randall as he takes on many challenges, against the background of a raw and developing China.”

The book is available for sale on Amazon, Barnes & Noble, Apple iBooks, Kobo, Nook, Google Play, and other online bookstores. Readers are encouraged to purchase their copy today: https://www.amazon.com/How-Lost-Kidneys-China-Overindulgent/dp/1959096303

To learn more about Randall’s adventures and receive updates on new book releases, visit: https://www.howilostmykidneysinchina.com. To connect with Randall, please visit: www.twitter.com/randallshanghai

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Randall Flores, Author of How I Lost My Kidneys In China – A Twenty-Five-Year Overindulgent Odyssey, Recognized as a Finalist in International Book Contest

Liquid Biopsy for Cancer Diagnostics Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVision

Liquid Biopsy for Cancer Diagnostics pipeline constitutes key companies continuously working towards developing Liquid Biopsy for Cancer Diagnostics treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Liquid Biopsy for Cancer Diagnostics Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

DelveInsight’s, Liquid Biopsy for Cancer Diagnostics – Competitive Landscape and Pipeline Analysis, 2023 report provides an understanding of the current competition, pipeline products, and changing market dynamics of the Liquid Biopsy for Cancer Diagnostics market in the 7 major pharmaceutical markets. The report also gives a brief competitive analysis of both the current and emerging products, to help understand the competition in the market.

 

Some of the key takeaways from the Liquid Biopsy for Cancer Diagnostics Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Liquid Biopsy for Cancer Diagnostics treatment therapies with a considerable amount of success over the years. Liquid Biopsy for Cancer Diagnostics Key players such as – Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVisionFirst, Therascreen PIK3CA test, ArcherMET, ExoDx Prostate Test, Resolution ctDx Lung assay, PlasmaSELECT 64, IvyGene DX Liver Cancer Test, LiquidHallmark test, FoundationOne Liquid, OncoBEAM, and others, are developing therapies for the Liquid Biopsy for Cancer Diagnostics treatment 
  • Liquid Biopsy for Cancer Diagnostics Emerging therapies such as – CancerIntercept Detect, Exact Science’s DNA methylation-based liquid biopsy test, Parsortix, Grail’s liquid biopsy cancer test, and others are expected to have a significant impact on the Liquid Biopsy for Cancer Diagnostics market in the coming years.   
  • On 2nd June 2022, GRAIL revealed a strategic partnership with AstraZeneca aimed at creating and marketing companion diagnostic (CDx) assays tailored for use alongside AstraZeneca’s treatments.

 

Liquid Biopsy for Cancer Diagnostics Overview

Liquid biopsy for cancer diagnostics is a non-invasive method used to detect and analyze tumor-related biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs), in bodily fluids like blood, urine, or saliva. This technique enables the detection, monitoring, and characterization of tumors without the need for invasive procedures like tissue biopsies. 

 

Get a Free Sample PDF Report to know more about Liquid Biopsy for Cancer Diagnostics Pipeline Assessment- https://www.delveinsight.com/sample-request/liquid-biopsy-for-cancer-diagnostics-pipeline-insight

 

Liquid Biopsy for Cancer Diagnostics Pipeline Therapeutics Assessment

  • Liquid Biopsy for Cancer Diagnostics Assessment by Product Type
  • Liquid Biopsy for Cancer Diagnostics By Stage and Product Type
  • Liquid Biopsy for Cancer Diagnostics Assessment by Route of Administration
  • Liquid Biopsy for Cancer Diagnostics By Stage and Route of Administration
  • Liquid Biopsy for Cancer Diagnostics Assessment by Molecule Type
  • Liquid Biopsy for Cancer Diagnostics by Stage and Molecule Type

 

DelveInsight’s Liquid Biopsy for Cancer Diagnostics Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration 

 

Key Competitors in Liquid Biopsy for Cancer Diagnostics Pipeline and Market 

  • Guardant Health
  • Roche
  • Neo Genomics
  • Qiagen
  • ArcherDX
  • Bio-Techne
  • Resolution Bioscience
  • Personal Genome Diagnostics
  • Laboratory for Advanced Medicine (LAM)
  • Lucence Diagnostics
  • Foundation Medicine Inc
  • Biocept
  • Sysmex Ionostics Inc
  • Veridex LLC (Janssen Diagnostics)
  • Biodesix
  • Pathway Genomics
  • Exact Sciences
  • Angle Plc
  • GRAIL Inc.
  • NuProbe
  • OncoCell MDx Inc
  • Merck
  • AmoyDx

 

Liquid Biopsy for Cancer Diagnostics Pipeline Analysis:

The Liquid Biopsy for Cancer Diagnostics pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Liquid Biopsy for Cancer Diagnostics treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liquid Biopsy for Cancer Diagnostics Treatment.
  • Liquid Biopsy for Cancer Diagnostics key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Liquid Biopsy for Cancer Diagnostics Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liquid Biopsy for Cancer Diagnostics market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Liquid Biopsy for Cancer Diagnostics product details are provided in the report. Download the Liquid Biopsy for Cancer Diagnostics pipeline report to learn more about the emerging Liquid Biopsy for Cancer Diagnostics therapies

 

Liquid Biopsy for Cancer Diagnostics Pipeline Market Drivers

  • Increasing prevalence of cancer
  • Increasing preference for non-invasive procedures
  • Availability of funding for liquid biopsy R&D

 

Liquid Biopsy for Cancer Diagnostics Pipeline Market Barriers

  • Lack of harmonization
  • The clinical utility of the test results
  • Lack of technical knowledge and expertise

 

Scope of Liquid Biopsy for Cancer Diagnostics Pipeline Drug Insight    

  • Coverage: Global
  • Key Liquid Biopsy for Cancer Diagnostics Companies: Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVisionFirst, Therascreen PIK3CA test, ArcherMET, ExoDx Prostate Test, Resolution ctDx Lung assay, PlasmaSELECT 64, IvyGene DX Liver Cancer Test, LiquidHallmark test, FoundationOne Liquid, OncoBEAM, and others
  • Key Liquid Biopsy for Cancer Diagnostics Therapies: CancerIntercept Detect, Exact Science’s DNA methylation-based liquid biopsy test, Parsortix, Grail’s liquid biopsy cancer test, and others
  • Liquid Biopsy for Cancer Diagnostics Therapeutic Assessment: Liquid Biopsy for Cancer Diagnostics current marketed and Liquid Biopsy for Cancer Diagnostics emerging therapies
  • Liquid Biopsy for Cancer Diagnostics Market Dynamics:  Liquid Biopsy for Cancer Diagnostics market drivers and Liquid Biopsy for Cancer Diagnostics market barriers 

 

Request for Sample PDF Report for Liquid Biopsy for Cancer Diagnostics Pipeline Assessment and clinical trials

 

Table of Contents

1

Liquid Biopsy for Cancer Diagnostics Report Introduction

2

Liquid Biopsy for Cancer Diagnostics Executive Summary

3

Liquid Biopsy for Cancer Diagnostics Overview

4

Liquid Biopsy for Cancer Diagnostics- Analytical Perspective In-depth Commercial Assessment

5

Liquid Biopsy for Cancer Diagnostics Pipeline Therapeutics

6

Liquid Biopsy for Cancer Diagnostics Late Stage Products (Phase II/III)

7

Liquid Biopsy for Cancer Diagnostics Mid Stage Products (Phase II)

8

Liquid Biopsy for Cancer Diagnostics Early Stage Products (Phase I)

9

Liquid Biopsy for Cancer Diagnostics Preclinical Stage Products

10

Liquid Biopsy for Cancer Diagnostics Therapeutics Assessment

11

Liquid Biopsy for Cancer Diagnostics Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Liquid Biopsy for Cancer Diagnostics Key Companies

14

Liquid Biopsy for Cancer Diagnostics Key Products

15

Liquid Biopsy for Cancer Diagnostics Unmet Needs

16 

Liquid Biopsy for Cancer Diagnostics Market Drivers and Barriers

17

Liquid Biopsy for Cancer Diagnostics Future Perspectives and Conclusion

18

Liquid Biopsy for Cancer Diagnostics Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Liquid Biopsy for Cancer Diagnostics drugs and therapies

 

 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Liquid Biopsy for Cancer Diagnostics Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVision

Dev Vyas, in collaboration with the Jupiter Research Institute, shapes a new era of financial technology and education for the future.

In this new era intertwined with rapid fintech development and market globalization, the Jupiter Research Institute has become a key force leading change. This story of innovation, pursuit, and collaboration centers on Dev Vyas, a financial pioneer born in Mumbai, who closely partners with the Jupiter Research Institute to draw a hopeful blueprint for the future.

Dev’s journey begins with his academic voyage, deeply rooted in his core values: perseverance, a thirst for knowledge, and a profound concern for society. Through diligent study at the University of Madras and Imperial College London, Dev not only built a solid foundation in financial knowledge but, more importantly, cultivated a keen insight into the financial markets and a sharp understanding of future technological trends.

When the Jupiter Research Institute sought a leader to guide the institution to the forefront of fintech innovation, Dev naturally became their top choice. His outstanding performance at Jupiter Asset Management in the UK, achievements under his leadership at Max Financial Services in India, and significant success in the Indian Institutional Professional Traders Live Trading Competition all profoundly demonstrated Dev’s strength and potential.

The Jupiter Research Institute chose Dev not only for his personal accomplishments but also for his vision and values that benefit the broader society. This perfectly aligns with the institute’s mission to shape the next generation of fintech leaders through education and training and to promote sustainable development in the financial markets.

Upon joining the Jupiter Research Institute, Dev injected his precise insights into the financial markets and passion for education into the institution’s daily operations. The projects he oversees are committed to providing top-tier financial education and investment training, exploring how cutting-edge technologies like blockchain and artificial intelligence can revolutionize financial services, enhance efficiency and security, and increase market transparency and fairness.

Under Dev’s leadership, the Jupiter Research Institute continuously expands the scope and impact of its education and training programs, establishing collaborations with globally renowned financial institutions and tech companies, and introducing the latest market practices and technology updates. The chapters written by Dev and the Jupiter Research Institute showcase how individuals and institutions, technology and education, markets and society can work together to innovate and contribute within the fintech sector, laying a foundation for the healthy development and stability of the global financial markets and truly achieving a win-win scenario for all parties involved.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Jupiter Research Institute
Contact Person: Johnny J
Email: Send Email
Country: India
Website: https://www.jambin.org/index.html

Security Matters (SMX) And PepsiCo Europe Work To Promote Sustainability Across Europe Supply Chain ($SMX)

Don’t be misled by SMX (Security Matters) PLC (NASDAQ: SMX; SMXWW) sub-dollar stock price. This company is doing groundbreaking work with some of the world’s largest global conglomerates. However, because SMX often touts this work only through SEC filings or an occasional social media post, those not following closely or willing to do some cursory due diligence will likely miss the news. And at the same time, the evidence for why SMX at current prices presents a value proposition too good to ignore.

That case was made stronger on March 20, 2024, when SMX filed about its excitement to share a pilot program with PepsiCo (NYSE: PEP) to deter counterfeiting and ensure that product authenticity is complete. Notably, the success of initial tests has moved the program toward finalizing an agreement to scale the technology across their operations and provide PEP accurate identification of marked PepsiCo packaging to validate supply chain transparency and safeguard brand integrity. A final deal could become a massive revenue-generating driver for SMX, considering the product volume associated with PEP and their intent to promote and track sustainability initiatives across their European supply chain. Important to the SMX value proposition, PEP appears interested in leveraging SMX’s invisible marker system in waste sorting to track closed-loop recycling and verify sustainability claims.

If a deal is made, it will be another tremendous client win for SMX, adding to a Who’s Who customer list interested in or already utilizing its blockchain-tech system to identify, sort, and pack waste. Considering the enormous success SMX has had in validating its technology with other global brands and agencies like Continental, the Perth Mint, the North American Flame Retardant Alliance (NAFRA), LVMH Métiers d’Art (OTC: LVMHF), and the Israeli Cotton Board, adding them to the long-term client list after its trial program may be more than likely; it’s probable. In other words, at roughly $0.14 today, catching SMX stock at these levels may be as ground floor as it gets. 

SMX Chosen For Technological Ingenuity

That’s not an overly ambitious assessment, considering that SMX was one of only six companies PEP chose to collaborate with to lend expertise and know-how to promote sustainability in its European supply chain. It’s no surprise that PEP would want to work with SMX, noting that, like them, SMX shares a vision of harnessing digital technology to expedite positive change and responsible use of resources to reduce waste and provide traceable verification to ensure company commitments are met in participating in a circular economy.

From an investor perspective, the most important takeaway is that SMX technology is being evaluated and chosen by these large companies for the right reasons. Foremost is that SMX technology connects tightly to their sustainability initiatives by leveraging a breakthrough solution that can uniquely solve sustainability and supply chain challenges across its vast distribution network. SMX CEO Haggai Alon commented about the inherent value of this win-win relationship with PEP, saying, “SMX is honoured to have been chosen to work with PepsiCo Labs to enable them to identify, track, sort packaging waste. We look forward to continuing our successful relationship and enabling PepsiCo Labs to enhance their packaging waste recycling to become more innovative, sustainable, and tangible through SMX’s breakthrough technology to ‘mark’ the plastic at virgin stage as well as at recycling and sorting facilities – enhancing the sorting capability, resulting in higher rates of plastic recycling content.”

SMX Is A Game Changer In Fostering A Circular Economy

Those new to SMX are behind the technological times. This company is a game-changer for companies committed to traceability, accountability, recycling, and fostering a global circular economy. They actually do more than that.

SMX invisible marker technology provides brand protection and uncompromising supply chain integrity, enhanced by blockchain inclusions that have led to its technology being described as “The Intelligence of Things,” a deserved tagline based on its comprehensive track and trace ecosystem to maintain supply chain quality assurance for virtually any raw material and end product.

Consider the technology as barcodes on steroids. That’s a meaningful comparison, considering the billions of dollars saved through efficiencies it provided. SMX is the next-generation barcode, so to speak. And it can be far more beneficial to miners, manufacturers, brands, and logistics than those long black lines ever were. Unlike a printed version on a package, SMX technology comprises a chemical-based, hidden “barcode” system with a “reader” to identify unique codes and create a blockchain record to store, maintain, and protect data ownership.

It works on metals, plastics, oils, fabric, and other raw materials. As important, the mark can’t be removed, destroyed, or altered, instead becoming a permanent part of a product’s DNA, providing companies throughout the supply chain buying, selling, or mining products the most efficient and reliable means of identifying where products started, where they went, and how they will be reused in their new life cycle. That’s the value driver that can’t be under-appreciated or undervalued. However, based on the current SMX share price, both appear almost entirely neglected. Still, while those opportunities are worth millions, evidenced by its recent roughly $5 million deal with R&I Trading, another potentially massive rev-gen opportunity is also in play inherent to the Homeland Security market.  

A Formidable Ally To Protect Country And Brand

From that market perspective, fighting against active boots on the ground is far less common than battling attacks through supply chain infiltration. And the consequences of the latter can be devastating. Remember, the vast profits made without supply chain checks and balances often support illicit activities. Not just those related to underground markets dealing in illegal products, either. Dollars made also support global terrorism, an area of concern needing no introduction to most. The worst part is that these dollars are raised daily through conventional manufacturing and transporting channels. While that result has been hard to stop, it’s no longer impossible. Thank SMX for that. 

They market precisely the type of technological asset needed to combat supply chain deficiencies and thwart untoward intentions. Doing so does more than expose the compelling value proposition; for growth stock investors, SMX’s abilities support the thesis that the path of least resistance for its shares is higher. That calculus is more than warranted; it’s justified. Keep in mind when appraising the SMX valuation disconnect that reports by Straits Research indicate that investments made to enhance homeland security are soaring, driven by an imperative need to address contemporary global security challenges. 

For instance, the United States’s budget allocation for homeland security will likely eclipse the $49.8 billion spent in 2021, highlighting its commitment to countering immersive threats. That’s just the United States. Billions more are in play from other countries, many of which have an immediate need to bolster national security infrastructures. And the opportunities in play extend beyond country defenses. Companies and sectors need protection, too. 

That includes potentially tremendous revenue-generating opportunities from the digital assets sector, potentially with sector companies like RIOT Platforms (Nasdaq: RIOT), Marathon Digital (Nasdaq: MARA), and CleanSpark (Nasdaq: CLSK). Due to their sector-user’s anonymity and ease of transfer, digital assets can significantly threaten global homeland security defenses. As noted, food and beverage companies like Pepsi, Coca-Cola (NYSE: KO), and others must also join the fight to ensure supply chain integrity. Remember, those behemoths do billions of dollars in transactions yearly, many of which could be compromised by supply chain vulnerabilities. In some way relevant to its means, every company can and should ally on the side of homeland protection.

Capitalizing On The Valuation Disconnect

It’s that totality of opportunity from the public and private sectors that exposes a valuation disconnect that is simply too compelling to ignore. Investors shouldn’t, either. SMX is a game-changer in global accountability and supply-chain security. And over the past two months, updates prove that they are accelerating an already ambitious mission by demonstrating that ingenuity can be more effective in winning the global war against supply chain destruction and terrorism with an indestructible invisible marker technology that can change how businesses, manufacturers, and trade operate.

The value of that contribution must be recognized and factored into every SMX appraisal. After all, it’s absolutely vital to ensure the shift to digital is seamless, safe, and transparent. And with SMX emerging as one of the, perhaps the only, company qualified and able to ensure that mission stays on course, this value proposition is worth seizing. In fact, considering the amount of revenue-generating opportunities in the SMX crosshairs, consider taking advantage sooner rather than later.

 

Disclaimers: Hawk Point Media Group, Llc. is responsible for the production and distribution of this content.  Hawk Point Media Group, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by  Hawk Point Media Group, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall  Hawk Point Media Group, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by  Hawk Point Media Group, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations.  Hawk Point Media Group, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content,  Hawk Point Media Group, Llc., its authors, contributors, or its agents, may be compensated  for preparing research, video graphics, and editorial content. HPM, LLC has been compensated three-thousand-five-hundred-dollars via bank wire by a third unrelated party to provide this research and/or editorial production coverage for SMX PLC. for a period starting on 04/05/24 and ending on 03/09/24. HPM LLC. was previously compensated two-thousand-five-hundred-dollars to provide similar services for a one month period starting on 4/30/24 and ending on 10/20/23. HPM LLC. was previously paid four-thousand-five-hundred-dollars via bank transfer by Trending Equities LLC for digital production and syndication services beginning on March 1, 2023 and ending on March 31, 2023. Thus, readers of this content should note that SMX PLC is portrayed favorably. As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that are attached to this content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Security Matters (SMX) And PepsiCo Europe Work To Promote Sustainability Across Europe Supply Chain ($SMX)

Emerging AI Healthcare Pioneers Promise Medical Breakthroughs and Investment Opportunities (CSE: TRUE)

Healthcare AI related stocks to keep an eye on include Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM)

In the realm of healthcare, the intersection of technology and education holds the key to unlocking unparalleled advancements and efficiencies. Treatment AI (OTCQB: TREIF) (CSE: TRUE) is potentially at the forefront of this exciting frontier, leveraging artificial intelligence (AI) to redefine medical education and diagnostic processes. The company’s latest achievements not only highlight the transformative power of AI in healthcare but also underscore a commitment to inclusivity and accuracy in medical diagnostics.

A New Benchmark in Medical Education

On March 20, 2024, Treatment.com announced a groundbreaking achievement from its headquarters in Vancouver, British Columbia. Its AI medical information support platform made headlines by participating in the “Objective Structured Clinical Examination” (OSCE) – a cornerstone of medical and nursing education globally. This exam tests the diagnostic aptitude of students in simulated medical scenarios, requiring them to assess and diagnose actors portraying patients with various conditions.

Treatment.com’s innovative approach saw a third-year non-medical college student equipped with the Treatment mobile app, stepping into the shoes of a medical student. This student was not only able to participate but also excelled in the OSCE, achieving a remarkable 92% success rate. The app guided the student through examinations of 12 simulated patients, enabling them to correctly identify the “1st most likely” diagnoses in 11 out of 12 cases. The diagnoses ranged from complex conditions such as colon cancer and acute myocardial infarction to diabetes and patellar tendonitis.

A Tool for Tomorrow’s Medical Professionals

The implications of this achievement are profound. Dr. Kevin Peterson, MD, MPH, Chief Medical Officer at Treatment.com, praised the AI software’s capability to process and analyze clinical data, transforming it into precise, actionable diagnoses. This technology represents a significant leap forward, providing medical professionals with a powerful tool that fits right in their pocket.

Dr. Essam Hamza, MD, CEO of Treatment.com AI, echoed this enthusiasm, highlighting the company’s dedication to revolutionizing healthcare delivery. The AI diagnostic engine’s integration into medical education is a testament to the trust placed in it by medical schools worldwide. This initiative not only prepares the next generation of healthcare professionals for success but also aims to enhance the quality and accessibility of healthcare services globally.

Expanding the Horizon

Beyond the OSCE triumph, Treatment.com’s vision extends to the broader healthcare landscape. The company’s Medical Education Suite (MES) offers a comprehensive platform for case-based clinical decision-making, testing, grading, and providing remedial support. The MES is designed to improve medical students’ performance in national exams, including the OSCE, while simultaneously reducing administrative burdens and costs for educational institutions.

The synergy between Treatment.com’s culturally sensitive AI approach to collecting family medical history and its advancements in medical education underscores a holistic strategy. By addressing both the nuances of individual patient backgrounds and the technical prowess of future medical professionals, Treatment.com is setting new standards for healthcare technology.

As we look forward to the deployment of new products and solutions from Treatment.com in the healthcare market, the potential for AI to transform the sector becomes increasingly evident. From making healthcare more equitable to enhancing the training of medical professionals, Treatment.com is at the helm of a healthcare revolution, ensuring that the future of medicine is not only technologically advanced but also universally accessible and culturally informed.

Through its innovative approach and commitment to excellence, Treatment.com AI Inc. seems to not just imagining the future of healthcare—it’s actively building it, ensuring that every advancement brings us closer to a world where healthcare is more effective, equitable, and accessible to all.

Other Healthcare AI related stocks to keep an eye on include Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM)

 

Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.

Sources: 

TRUE

https://finance.yahoo.com/quote/TRUE.CN/

https://finance.yahoo.com/news/treatment-ai-passes-medical-school-123000812.html

Media Contact
Company Name: TheBullReport
Contact Person: Jason Roy
Email: info@thebullreport.com
City: Dallas
State: Texas
Country: United States
Website: https://www.thebullreport.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Emerging AI Healthcare Pioneers Promise Medical Breakthroughs and Investment Opportunities (CSE: TRUE)

Kelco Cabinets Shares Tips on Maintaining kitchen Cabinets for Lasting Beauty

Kelco Cabinets Shares Tips on Maintaining kitchen Cabinets for Lasting Beauty
Kelco Cabinets is a top-rated cabinet design company. In a recent update, the company shared tips on maintaining kitchen cabinets for lasting beauty.

Springfield, MO – In a website post, Kelco Cabinets shared tips on maintaining kitchen cabinets for lasting beauty.

The cabinet contractor Springfield noted that one of the most crucial things to remember when maintaining kitchen cabinets is to use the right products. Harsh chemicals and abrasive cleaners may damage the cabinets’ finish and cause discoloration or scratches. Instead, opt for gentle cleaners specifically designed for wooden or painted surfaces. These cleaners will effectively remove grease, dirt, or food residue while keeping the cabinets’ finish intact. 

The Springfield cabinet contractor mentioned that regular maintenance is key to keeping kitchen cabinets looking their best. It’s recommended that the cabinets be cleaned and polished at least once a month to prevent a buildup of grease and grime. When cleaning, pay special attention to areas near the stove and sink, as these are more prone to splatters and spills. It’s also essential to dust the cabinets regularly to avoid dust and other debris from accumulating on the surfaces. 

The Springfield MO cabinet technician added that proper storage and organization can also contribute to the longevity of kitchen cabinets. Cluttered cabinets can unnecessarily strain the doors and hinges, causing them to loosen. It’s essential to declutter and organize the cabinets regularly to ensure items are not stacked or shoved too tightly, which can cause damage. Drawer dividers or cabinet organizers can also help reduce clutter. 

About Kelco Cabinets

Kelco Cabinets is a leading cabinet design company. They specialize in creating high-quality custom cabinets for residential and commercial spaces. The design process initiates with a deep understanding of the client’s unique needs and vision. The crew works closely with each customer to translate their ideas into beautiful and functional cabinet designs. From modern and sleek to traditional and timeless, the firm offers various styles to suit any taste.

Kelco Cabinets

 1926 W Woodland St, Springfield, MO 65807

 (417) 557-3341

Media Contact
Company Name: Kelco Cabinets
Contact Person: Preston Kelsch
Email: Send Email
Phone: (417) 557-3341
Address:1926 W Woodland St
City: Springfield
State: Missouri
Country: United States
Website: https://www.kelcocabinets.com/